---
provider: openai
model: o3-deep-research-2025-06-26
cached: false
start_time: '2025-11-20T10:47:58.040268'
end_time: '2025-11-20T11:04:35.311690'
duration_seconds: 997.27
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    top_p: 1.0
citation_count: 67
---

## Question

Here is a pathway that describes how a drug might affect a disease:

**Pathway:** SmallMolecule: Clofibrate | affects | Gene: ALB | affects | SmallMolecule: Myricetin | contributes_to | Disease: metabolic dysfunction-associated steatotic liver disease

**Drug:** Clofibrate
**Disease:** metabolic dysfunction-associated steatotic liver disease

What is the biological plausibility of this drug-disease relationship?

Score on a scale of:
- 1 = Totally implausible (doesn't make sense biologically and no support in literature)
- 2 = Seems implausible (no support in literature)
- 3 = Seems plausible (no support in literature)
- 4 = Very plausible (some support in literature)
- 5 = Totally plausible (mechanism already described)

Consider:
- Has this exact mechanism been described in the literature?
- Do all, most, or some of the steps in the pathway have support in the literature?
- Do all, most, or some of the steps seem biologically plausible even without direct literature support?


## Output

# Introduction  
The proposed pathway links **Clofibrate** (a small-molecule drug) to **metabolic dysfunction-associated steatotic liver disease (MASLD)** through intermediate effects on the **ALB gene** (albumin) and the **small-molecule myricetin**. MASLD is the recently adopted term encompassing non-alcoholic fatty liver disease (NAFLD) with metabolic dysfunction ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045356/#:~:text=to%20address%20these%20issues%20but,the%20disease%20in%20the%20future)). In essence, the pathway suggests: **Clofibrate** affects **albumin (ALB)**, which in turn affects **myricetin**, and myricetin contributes to **MASLD** progression or mitigation. To assess the **biological plausibility** of this drug–disease relationship, we must examine each step of the mechanism for support in current biomedical literature and mechanistic reasoning. Key questions include: *Has this exact mechanism been documented?* *Do the individual links have experimental or observational support?* and *Are the steps biologically sensible even if not directly proven?* Below, we break down the pathway into its components, review relevant evidence (especially recent 2023–2024 findings), and then provide an integrated plausibility assessment with a score from 1 (implausible) to 5 (fully plausible). Proper definitions and context for each element are provided first, followed by analysis of the interactions and expert insights.

## Clofibrate: PPAR-α Agonist and Metabolic Effects  
**Clofibrate** is a fibrate drug historically used to treat hyperlipidemia (high triglycerides and cholesterol). Pharmacologically, clofibrate is a prodrug converted to clofibric acid, which activates the peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor that regulates lipid metabolism. PPAR-α activation upregulates genes for fatty acid β-oxidation in liver peroxisomes and mitochondria, thereby **lowering plasma triglycerides and raising HDL cholesterol** ([synapse.koreamed.org](https://synapse.koreamed.org/articles/1016286#:~:text=PPAR,C%29%20levels)). Fibrate drugs (including clofibrate, gemfibrozil, fenofibrate, etc.) have been in clinical use for over 40 years to manage dyslipidemia ([synapse.koreamed.org](https://synapse.koreamed.org/articles/1016286#:~:text=PPAR,C%29%20levels)). By promoting fatty acid breakdown and modulating lipid transport, clofibrate can influence liver fat content and metabolic homeostasis. Indeed, in classic experimental models, clofibrate was shown to **reverse fatty liver infiltration**. For example, in rats fed a diet that induces fatty liver (orotic acid diet), adding clofibrate restored normal liver histology: within ~2 weeks, hepatic triglyceride levels fell back to control levels and fat droplets in liver cells disappeared ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/839735/#:~:text=Immunoelectrophoretic%20determinations%20show%20that%20the,fed%20control%20levels)). This demonstrates a **plausible mechanism for clofibrate reducing liver steatosis** via PPAR-α–mediated enhancement of lipid clearance. 

However, clinical outcomes with clofibrate have been mixed and its use declined due to side effects (e.g. elevated risk of gallstones and gastrointestinal issues) ([synapse.koreamed.org](https://synapse.koreamed.org/articles/1016286#:~:text=There%20was%20a%20marked%20association,possible%20mechanism%20of%20lithogenicity%20could)) ([synapse.koreamed.org](https://synapse.koreamed.org/articles/1016286#:~:text=statins,considerable%20anticipation%20for%20the%20results)). Newer fibrates like **fenofibrate** are preferred. Notably, fenofibrate has been tested for NAFLD/MASLD management. A 2025 systematic review of patients with MASLD found that **fenofibrate had no significant improvement in liver enzymes or histology compared to other treatments**, although it did lower triglycerides as expected ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=From%20initially%20screened%20395%20articles%2C,with%20a%20significantly%20greater%20decrease)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=controls)). Fenofibrate was essentially “MASLD-neutral” in terms of reducing liver fat, especially when compared to agents like pioglitazone or omega-3 which actively reduce liver fat ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=IU%2FL%20%5B95,Fenofibrate%20was%20associated%20with%20comparable)). This suggests that while PPAR-α agonists are metabolically active drugs, their direct clinical benefit in MASLD is limited or not clearly demonstrated in humans. Nonetheless, the ability of clofibrate and similar agents to modify lipid metabolism means it *could* influence fatty liver disease pathways, at least at a biochemical level. The specific pathway in question posits an *indirect* route involving albumin and myricetin, which we will explore next.

## Albumin (ALB Gene) – Role in Drug and Nutrient Transport  
The **ALB gene** encodes **albumin**, the most abundant plasma protein produced by the liver. Albumin serves critical transport functions: it binds and carries a wide range of small molecules – including hormones, drugs, fatty acids, and nutrients – in the bloodstream ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=Human%20serum%20albumin%20,Sudlow%27s%20Site%20II%20are%20the)). By forming stable complexes with ligands, albumin dramatically alters their distribution, free (active) concentration, and elimination ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=Human%20serum%20albumin%20,Sudlow%27s%20Site%20II%20are%20the)). Albumin has specific binding sites (Sudlow’s sites I and II) that accommodate many compounds ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=match%20at%20L146%20most%20important,to%20HSA%20with%20higher%20affinity)). In the context of the proposed pathway, albumin is the intermediary that **Clofibrate is said to affect**, and that in turn **affects myricetin**. There are two main possibilities for “Clofibrate affects albumin”: (1) **transcriptional regulation** – clofibrate (via PPAR-α activation) might influence albumin gene expression or the liver’s capacity to produce albumin; or (2) **direct binding or competition** – clofibrate and albumin interact physically, which could affect albumin’s binding of other molecules.

**Binding interactions:** Clofibrate (specifically its active form clofibric acid) is highly protein-bound in plasma, predominantly to albumin. Pharmacokinetic studies show that clofibrate can **displace other albumin-bound drugs**. For example, co-administration of clofibrate in humans displaced the anticoagulant warfarin from albumin binding sites, increasing warfarin’s free fraction in plasma by about **13%** ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/480183/#:~:text=prothrombin,increase%20in%20the)). This displacement is a classic protein-binding interaction and confirms that clofibrate avidly binds to albumin. In practical terms, clofibrate occupying albumin means fewer binding sites available for other compounds. If myricetin also binds to albumin, clofibrate could compete with or modify that binding. Indeed, **myricetin is known to form stable complexes with human serum albumin** at Sudlow’s Site I ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=most%20important%20drug%E2%80%90binding%20regions%20on,to%20HSA%20with%20higher%20affinity)). Recent biophysical research (2024) quantified this interaction: myricetin’s binding constant to albumin is *K* ≈ 1.3×10^5 L/mol ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=match%20at%20L407%20agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1)), indicating strong affinity. At physiological albumin concentration (~40 g/L, or ~600 µM), the vast majority of myricetin in the bloodstream would be bound to albumin (modeling suggests well over 95–99% binding under such conditions) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1)). In other words, **albumin dramatically buffers myricetin’s free levels** in blood. This is typical for polyphenols and many drugs – albumin binding slows their clearance and limits free distribution to tissues ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=Human%20serum%20albumin%20,Sudlow%27s%20Site%20II%20are%20the)). 

**Regulatory interactions:** There is little direct evidence that clofibrate substantially changes albumin gene expression. Albumin is a constitutive liver protein, and while severe liver metabolic changes or damage can alter albumin synthesis, fibrate drugs are not reported to hugely up- or down-regulate albumin production in normal settings. If anything, successful treatment of liver dysfunction could *normalize* albumin levels (since advanced fatty liver or NASH can impair liver synthetic function, leading to low albumin in late stages). It’s biologically plausible that if clofibrate improves liver metabolic health (as seen in rodent models ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/839735/#:~:text=Immunoelectrophoretic%20determinations%20show%20that%20the,fed%20control%20levels))), albumin synthesis might improve, but this is a secondary effect and not well documented in literature as a direct PPAR-α gene target. Thus, **the more relevant “affect” of clofibrate on albumin is likely through binding interactions** – clofibrate uses albumin as a carrier and can alter albumin’s binding of other molecules. 

In summary, **Albumin’s role in this pathway is as a carrier that links clofibrate and myricetin**. Both substances bind to albumin in plasma, so their interplay could be competitive. Clofibrate’s presence could either displace myricetin from albumin or, conversely, occupy sites that prevent myricetin binding – influencing how much free myricetin is available to tissues. This is a biologically **plausible** interaction given that clofibrate and myricetin share a binding partner in albumin, and such drug–flavonoid interactions have precedent (e.g., many drugs displace bilirubin or other ligands from albumin). Next, we examine myricetin’s role in liver disease to complete the chain of logic.

## Myricetin and MASLD (Metabolic Liver Disease)  
**Myricetin** is a naturally occurring flavonoid (a type of polyphenolic compound) found in many fruits, vegetables, tea, and berries. It is known for potent **antioxidant and anti-inflammatory properties**, and has been researched for various health benefits. In the context of liver metabolism, myricetin has drawn attention as a potential therapeutic or preventive agent for fatty liver disease. Preclinical studies (cell culture and animal models) have repeatedly shown that myricetin can **ameliorate metabolic dysfunction in the liver**:

- **Reduction of steatosis (fat accumulation):** Dietary myricetin supplementation in obese or high-fat diet models significantly **reduces liver fat content**. For example, mice on a high-fat diet developed hepatic steatosis, but when myricetin (0.12% of diet) was added for 12 weeks, it *significantly alleviated fatty liver*, decreasing liver triglyceride accumulation and improving liver histology ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=high,177%20genes%20which%20were%20involved)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=treatment%20significantly%20alleviated%20HFD,nuclear%20Nrf2%20translocation%2C%20increased%20the)). The treated mice had fewer fat droplets in hepatocytes and lower lipid peroxidation levels than untreated controls ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=treatment%20significantly%20alleviated%20HFD,nuclear%20Nrf2%20translocation%2C%20increased%20the)). Another study in a NASH (non-alcoholic steatohepatitis) mouse model showed that myricetin-treated mice had **lower NAFLD activity scores and less lipid accumulation in the liver** compared to untreated NASH mice ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid)). Oil Red O staining of liver tissue confirmed that myricetin markedly **decreased the fat droplets in hepatocytes** in these diseased mice ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid)).

- **Anti-inflammatory and anti-fibrotic effects:** Myricetin also combats the inflammation and fibrosis aspects of fatty liver progression (i.e., MASLD advancing to MASH – steatohepatitis). In the NASH mouse model, myricetin treatment led to reduced inflammatory cell infiltration and fewer inflammatory cytokines in the liver ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=match%20at%20L427%20were%20remarkably,staining%2C%20lipid)) ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=2C%2CE%29,amounts%20of%20hepatic%20macrophages%20were)). It modulated macrophages toward an anti-inflammatory (“M2”) phenotype, which correlated with less liver injury ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=macrophage%20polarization%20and%20its%20relative,Mechanically%2C%20myricetin)) ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=therefore%20mitigated%20NASH%20and%20hepatic,induced%20NASH%20model%20in%20mice)). Additionally, markers of hepatic fibrosis (such as collagen deposition and pro-fibrotic gene expression) were significantly downregulated with myricetin, indicating a protective effect against the development of scar tissue ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=match%20at%20L483%20treated%20NASH,9%29%2C%20and)). These actions suggest myricetin can *mitigate* steatohepatitis and its complications.

- **Molecular mechanisms:** Mechanistically, myricetin influences several pathways relevant to metabolic dysfunction. It has been shown to activate **AMP-activated protein kinase (AMPK)** and **Nrf2** signaling in liver cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=and%20increased%20antioxidative%20enzyme%20activities%2C,peroxisome%20and%20the%20PPAR%20signaling)). Activation of AMPK leads to inhibition of lipid synthesis genes (like SREBP-1c and fatty acid synthase), thereby reducing new fat accumulation. Indeed, one study noted myricetin normalized expression of genes involved in lipid metabolism and down-regulated PPAR-γ (which promotes adipogenesis) in the liver ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=and%20increased%20antioxidative%20enzyme%20activities%2C,peroxisome%20and%20the%20PPAR%20signaling)). Myricetin’s activation of Nrf2 increases antioxidant defenses (e.g. upregulating HO-1 and NQO1 enzymes) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=and%20increased%20antioxidative%20enzyme%20activities%2C,of%20PPAR%CE%B3%2C%20and%20normalized%20the)), reducing oxidative stress in fatty liver. There is also evidence that myricetin’s benefits in alcoholic FLD and NAFLD involve decreasing CYP2E1 (which generates reactive oxygen species) and improving fatty acid oxidation ([www.spandidos-publications.com](https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=In%20the%20liver%2C%20alcohol%20is,3%20%29%20%28%2058%2C43)) ([www.spandidos-publications.com](https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=recent%20years,37%20%2C%2058)). In cultured liver cells, myricetin attenuated fat accumulation induced by ethanol by **reducing fatty acid biosynthesis** enzymes ([www.spandidos-publications.com](https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=match%20at%20L661%2038%C2%A0%20,Article%20%3A%20Google%20Scholar)). Overall, these molecular actions underpin the observed physiological improvements. 

Given this body of evidence, myricetin is frequently described in research literature as a promising natural **intervention for fatty liver disease**. For instance, a 2025 review in *Molecular Medicine Reports* states that *“myricetin not only relieves acute liver injury but also plays a vital role in treating AFLD and NAFLD”* ([www.spandidos-publications.com](https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=dietary%20structure%20of%20an%20individual%2C,37%20%2C%2058)). While human clinical trials are still lacking, the consensus from animal studies is that myricetin can counteract key pathogenic processes in MASLD (steatosis, inflammation, oxidative stress, and fibrosis). Therefore, the **link between myricetin and MASLD is biologically plausible and supported by multiple studies** – myricetin has a beneficial influence on the disease process.

## Evidence for Each Step in the Proposed Pathway  
To evaluate the overall drug–disease relationship (Clofibrate → MASLD) via the pathway **Clofibrate – ALB – Myricetin – MASLD**, we examine the evidence for each individual step:

- **Step 1: Clofibrate affects ALB (albumin)** – *Supported/plausible.* Clofibrate’s primary known “effect” on albumin is through *binding interactions*. Clofibrate (as clofibric acid) binds strongly to human serum albumin, which can alter albumin’s binding of other molecules. Empirical evidence showed clofibrate displacing warfarin from albumin, indicating high affinity for the same binding sites ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/480183/#:~:text=prothrombin,increase%20in%20the)). This implies clofibrate occupies albumin significantly in plasma. There is no direct literature stating clofibrate upregulates the ALB gene, but improving liver function with clofibrate could indirectly normalize albumin levels. Overall, it **makes biological sense** that clofibrate and albumin interact, and this is backed by pharmacologic studies on protein binding. 

- **Step 2: ALB affects Myricetin** – *Supported.* Albumin’s effect on myricetin is well documented as a binding/carrier effect. Human albumin binds myricetin with high affinity, resulting in most myricetin being albumin-bound in circulation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=match%20at%20L407%20agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1)). By sequestering myricetin, albumin can modulate how much free myricetin is available to tissues (including the liver). This step is **strongly supported by biochemical studies**: e.g., >94–99% of myricetin (and its metabolites) can be protein-bound under physiological conditions ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1)). In practical terms, if albumin levels or binding site occupancy change (due to a drug like clofibrate), it could influence myricetin’s kinetics. Thus, the idea that albumin “affects” myricetin is **biologically and chemically plausible**, essentially through binding competition or transport capacity.

- **Step 3: Myricetin contributes to MASLD** – *Supported.* There is considerable scientific literature supporting myricetin’s role in influencing MASLD/NAFLD outcomes. As detailed above, myricetin consistently **ameliorates fatty liver disease** in experimental models ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=treatment%20significantly%20alleviated%20HFD,nuclear%20Nrf2%20translocation%2C%20increased%20the)) ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid)). It contributes to reduced liver fat, inflammation, and fibrosis. Whether we say “contributes to” disease in a positive therapeutic sense (improving it) or potentially as part of its pathology, the weight of evidence leans strongly toward myricetin being beneficial (protective) rather than a cause of MASLD. No studies suggest myricetin causes or worsens MASLD; instead it’s being explored as a treatment. Therefore, it is **very plausible** that the presence (or absence) of myricetin has an impact on the progression of metabolic fatty liver disease. This step has direct literature support, including 2020–2024 studies demonstrating myricetin’s mechanisms and effects in NAFLD/NASH models ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid)) ([www.spandidos-publications.com](https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=dietary%20structure%20of%20an%20individual%2C,37%20%2C%2058)).

Integrating these steps: The pathway posits that **Clofibrate could influence MASLD indirectly by altering myricetin’s activity/bioavailability via albumin**. For example, if a patient on clofibrate also has myricetin in their diet, clofibrate might compete for albumin binding, potentially increasing free myricetin levels (if clofibrate displaces myricetin). Increased free myricetin could enhance its delivery to the liver and amplify its beneficial effects on reducing steatosis/inflammation. This scenario would be a *positive* synergy, though it’s hypothetical and not demonstrated in studies. Conversely, if clofibrate somehow raised albumin expression or binding capacity, it might sequester myricetin more strongly, possibly reducing tissue uptake – but again, this exact mechanism hasn’t been reported in literature. The key point is that **each link in the chain is reasonable and grounded in known biology**, even though the full chain (“clofibrate → albumin → myricetin → improvement in MASLD”) has not, to our knowledge, been experimentally verified or described in a publication.

## Expert Analysis and Current Perspectives  
No publication to date outlines the exact mechanism connecting clofibrate, albumin, myricetin, and MASLD in one continuous pathway. This appears to be a novel or hypothetical association, possibly arising from a knowledge graph or inferred relationship. However, experts in metabolic liver disease and pharmacology would likely find the connection **credible on theoretical grounds** given what is known: 

- **Overlap in metabolic targets:** Clofibrate (through PPAR-α) and myricetin (through AMPK/Nrf2 and possibly PPAR modulation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=and%20increased%20antioxidative%20enzyme%20activities%2C,peroxisome%20and%20the%20PPAR%20signaling))) both act on pathways that regulate lipid metabolism and inflammation. There is a conceptual synergy if both were present – one could imagine a combination of a fibrate drug and a dietary polyphenol providing complementary benefits in MASLD. In fact, researchers are actively studying combinations of metabolic therapies (e.g., fibrates, statins, antioxidants, etc.) for NAFLD management ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=From%20initially%20screened%20395%20articles%2C,with%20a%20significantly%20greater%20decrease)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=controls)). While clofibrate specifically is less used now, the class of fibrates is of interest, and natural compounds like myricetin are being investigated as *adjuvants* in metabolic syndrome.

- **Current applications:** Clinically, clofibrate is largely of historical interest, but fenofibrate (a related PPAR-α agonist) is sometimes considered for NAFLD patients with severe hypertriglyceridemia. Experts note that fenofibrate’s effect on liver fat has been neutral, but it **safely improves blood lipids in MASLD patients** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=controls)). On the other hand, expert opinion on polyphenols like myricetin is increasingly positive – these compounds are seen as low-risk interventions that target oxidative stress and inflammation in MASLD. For instance, curcumin and resveratrol (similar natural polyphenols) have entered clinical trials for NAFLD ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39204178/#:~:text=multifaceted%20roles%20of%20cholesterol%20metabolism,future%20research%20and%20clinical%20applications)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39204178/#:~:text=recent%20advancements%20in%20understanding%20these,natural%20products%20in%20MASLD%2C%20providing)). Myricetin itself is not yet in large clinical trials, but **preclinical data have built a compelling case** for its efficacy ([www.spandidos-publications.com](https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=dietary%20structure%20of%20an%20individual%2C,37%20%2C%2058)). Authoritative reviews (2020–2023) on NAFLD therapeutics often mention flavonoids as a promising area, aligning with the view that boosting antioxidant capacity (like via Nrf2 activation, which myricetin does ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=and%20increased%20antioxidative%20enzyme%20activities%2C,of%20PPAR%CE%B3%2C%20and%20normalized%20the))) is a valid strategy to counteract fatty liver progression.

- **Expert caution:** It should be noted that while each piece is plausible, experts would caution that *correlation is not causation*. Just because clofibrate binds albumin and albumin binds myricetin, it doesn’t guarantee a meaningful physiological interaction. The timing, dosing, and relative concentrations matter. For any in vivo effect, clofibrate and myricetin would have to be present concurrently. If a patient isn’t consuming myricetin (or its levels are low), clofibrate’s effect on albumin has no relevance to MASLD via this route. Additionally, albumin is usually abundant and not a limiting factor unless in advanced liver disease. So, an expert might say the pathway is **biologically plausible but would need experimental validation to confirm any impact on disease outcomes**. They might look for evidence such as: does co-administration of clofibrate and myricetin in an animal model yield better MASLD improvement than either alone? Such studies aren’t documented yet.

## Plausibility Score and Conclusion  
Considering the points above, we now rate the biological plausibility of the **Clofibrate–MASLD relationship via ALB and myricetin** on the 1–5 scale:

- The **exact combined mechanism has not been described** in literature (so it’s not a well-known or proven pathway, precluding a score of 5).  
- **Most of the individual steps have support** in the literature: Clofibrate’s binding to albumin is documented ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/480183/#:~:text=prothrombin,increase%20in%20the)), albumin’s binding of myricetin is documented ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=match%20at%20L407%20agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1)), and myricetin’s impact on fatty liver disease is well-supported ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid)). This partial support elevates it above a purely speculative link.  
- **All of the steps are biologically plausible** based on current understanding, even where direct literature evidence is thin (e.g. clofibrate altering albumin expression is speculative but not implausible given metabolic effects). There is no step that “doesn’t make sense” biologically; nothing contradicts known physiology (hence it’s not in the implausible range of 1–2).

**Plausibility Score: 4 (Very plausible).** 

We judge this pathway to be *very plausible* biologically, meaning it makes sense mechanistically and some elements are supported by existing research, though the complete mechanism has not been explicitly demonstrated. In summary, **Clofibrate’s ability to modulate lipid metabolism (via PPAR-α) and its strong albumin binding, combined with albumin’s role in transporting myricetin, and myricetin’s beneficial effects on steatotic liver disease, form a chain of interactions that is coherent with current scientific knowledge**. There is **some literature support for each link** (binding studies, animal experiments), but future research would be needed to confirm that clofibrate clinically influences MASLD outcomes through this exact pathway. If such a drug-diet interaction were confirmed, it could open interesting possibilities (for example, using fibrate drugs alongside polyphenol-rich diets to synergistically treat MASLD). For now, we can conclude that the relationship is **biologically credible** and merits a high plausibility rating, albeit not the maximal score since it remains to be directly verified.

**References:**

1. Kumar M. *et al.* (2025). *Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis*. **Indian J Endocrinol Metab.** 29(3):268-275. DOI:10.4103/ijem.ijem_528_24  ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=From%20initially%20screened%20395%20articles%2C,with%20a%20significantly%20greater%20decrease)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=controls)) (Fenofibrate showed neutral effect on MASLD liver fat but lowered triglycerides, suggesting fibrates’ limited direct impact on fatty liver in humans, though safe).  

2. Issemann & Green (1990) via KoreaMed Synapse (2012). *PPAR-α agonists (clofibrate, gemfibrozil, etc.) have been used as lipid-lowering agents for >40 years due to lowering TG and raising HDL* ([synapse.koreamed.org](https://synapse.koreamed.org/articles/1016286#:~:text=PPAR,C%29%20levels)). Also noted clofibrate’s historical trials and side effects ([synapse.koreamed.org](https://synapse.koreamed.org/articles/1016286#:~:text=statins,considerable%20anticipation%20for%20the%20results)).  

3. Bellaire CL *et al.* (1979). *Reversal of orotic acid-induced fatty liver in rats by clofibrate.* **J Clin Invest.** 64(2):409-418. PMID:839735  ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/839735/#:~:text=Immunoelectrophoretic%20determinations%20show%20that%20the,fed%20control%20levels)). (Clofibrate added to diet reversed fatty liver in rats, restoring normal liver histology and triglyceride levels – demonstrates clofibrate’s mechanism in reducing hepatic steatosis in vivo).  

4. Dombi Á *et al.* (2024). *Interaction of myricetin and metabolites with serum albumin, CYP enzymes, and OATP transporters.* **Pharmacol Res Perspect.** 12(5):e0070021. DOI:10.1002/prp2.70021  ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=match%20at%20L407%20agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1)). (Found myricetin forms stable complexes with human serum albumin, K ~1.3×10^5 L/mol, meaning at body albumin levels, myricetin is >95% bound to albumin; significant as it affects myricetin’s pharmacokinetics).  

5. Yao Q *et al.* (2020). *Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine NASH Model*. **Front. Med.** 7:71. DOI:10.3389/fmed.2020.00071  ([www.frontiersin.org](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid)). (In a diet-induced NASH mouse model, myricetin treatment significantly reduced liver fat accumulation, inflammation, and fibrosis markers; treated mice had lower NAFLD activity scores and improved histology compared to untreated NASH mice).  

6. Lv Q *et al.* (2019). *Myricetin ameliorates ethanol-induced lipid accumulation in liver cells by reducing fatty acid biosynthesis*. **Mol Nutr Food Res.** 63(17):e1801393. DOI:10.1002/mnfr.201801393  ([www.spandidos-publications.com](https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=match%20at%20L661%2038%C2%A0%20,Article%20%3A%20Google%20Scholar)). (Cell study showing myricetin activates AMPK and reduces SREBP-mediated lipogenesis under ethanol exposure, supporting its role in preventing fatty liver changes).  

7. Molecular Medicine Reports (2025). *Role of myricetin in fatty liver disease* ([www.spandidos-publications.com](https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=dietary%20structure%20of%20an%20individual%2C,37%20%2C%2058)). (Review stating myricetin alleviates both alcoholic and non-alcoholic fatty liver disease, citing its ability to reduce oxidative stress, inflammation, and lipid accumulation in the liver).  

8. Säll C *et al.* (1985). *Clofibrate displaces warfarin from plasma proteins in man: a displacement interaction*. **Br J Clin Pharmacol.** 19(5):609-613. PMID:480183  ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/480183/#:~:text=prothrombin,increase%20in%20the)). (Demonstrated that clofibrate coadministration led to a 13% increase in free warfarin levels by displacing it from albumin binding sites, evidence of clofibrate’s strong albumin binding).  

9. Eslam M *et al.* (2023). *A Delphi consensus statement on new fatty liver disease nomenclature*. **J Hepatol.** 79(5):1151-1167. DOI:10.1016/j.jhep.2023.06.006  ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045356/#:~:text=to%20address%20these%20issues%20but,the%20disease%20in%20the%20future)). (International liver societies renamed NAFLD to MASLD – metabolic dysfunction-associated steatotic liver disease – in 2023 to better reflect pathogenesis).  

10. Xia S-F *et al.* (2016). *Regressive effect of myricetin on hepatic steatosis in high-fat diet-fed mice*. **Nutrients.** 8(12):799. DOI:10.3390/nu8120799  ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=treatment%20significantly%20alleviated%20HFD,nuclear%20Nrf2%20translocation%2C%20increased%20the)). (Myricetin supplementation for 12 weeks significantly reduced liver fat and oxidative stress in obese mice; also modulated expression of 177 genes including those in PPAR signaling and peroxisome pathways, indicating a broad beneficial metabolic reprogramming in the liver).

## Citations

1. AnnotationURLCitation(end_index=523, start_index=369, title='Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11045356/#:~:text=to%20address%20these%20issues%20but,the%20disease%20in%20the%20future')
2. AnnotationURLCitation(end_index=2107, start_index=2009, title='KoreaMed Synapse', type='url_citation', url='https://synapse.koreamed.org/articles/1016286#:~:text=PPAR,C%29%20levels')
3. AnnotationURLCitation(end_index=2343, start_index=2245, title='KoreaMed Synapse', type='url_citation', url='https://synapse.koreamed.org/articles/1016286#:~:text=PPAR,C%29%20levels')
4. AnnotationURLCitation(end_index=2986, start_index=2828, title='Reversal of orotic acid-induced fatty liver in rats by clofibrate - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/839735/#:~:text=Immunoelectrophoretic%20determinations%20show%20that%20the,fed%20control%20levels')
5. AnnotationURLCitation(end_index=3457, start_index=3289, title='KoreaMed Synapse', type='url_citation', url='https://synapse.koreamed.org/articles/1016286#:~:text=There%20was%20a%20marked%20association,possible%20mechanism%20of%20lithogenicity%20could')
6. AnnotationURLCitation(end_index=3595, start_index=3458, title='KoreaMed Synapse', type='url_citation', url='https://synapse.koreamed.org/articles/1016286#:~:text=statins,considerable%20anticipation%20for%20the%20results')
7. AnnotationURLCitation(end_index=4105, start_index=3927, title='Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=From%20initially%20screened%20395%20articles%2C,with%20a%20significantly%20greater%20decrease')
8. AnnotationURLCitation(end_index=4199, start_index=4106, title='Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=controls')
9. AnnotationURLCitation(end_index=4523, start_index=4373, title='Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=IU%2FL%20%5B95,Fenofibrate%20was%20associated%20with%20comparable')
10. AnnotationURLCitation(end_index=5461, start_index=5315, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=Human%20serum%20albumin%20,Sudlow%27s%20Site%20II%20are%20the')
11. AnnotationURLCitation(end_index=5744, start_index=5598, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=Human%20serum%20albumin%20,Sudlow%27s%20Site%20II%20are%20the')
12. AnnotationURLCitation(end_index=5996, start_index=5839, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=match%20at%20L146%20most%20important,to%20HSA%20with%20higher%20affinity')
13. AnnotationURLCitation(end_index=7037, start_index=6929, title='Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/480183/#:~:text=prothrombin,increase%20in%20the')
14. AnnotationURLCitation(end_index=7623, start_index=7448, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=most%20important%20drug%E2%80%90binding%20regions%20on,to%20HSA%20with%20higher%20affinity')
15. AnnotationURLCitation(end_index=7929, start_index=7753, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=match%20at%20L407%20agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1')
16. AnnotationURLCitation(end_index=8320, start_index=8164, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1')
17. AnnotationURLCitation(end_index=8678, start_index=8532, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=Human%20serum%20albumin%20,Sudlow%27s%20Site%20II%20are%20the')
18. AnnotationURLCitation(end_index=9492, start_index=9334, title='Reversal of orotic acid-induced fatty liver in rats by clofibrate - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/839735/#:~:text=Immunoelectrophoretic%20determinations%20show%20that%20the,fed%20control%20levels')
19. AnnotationURLCitation(end_index=11647, start_index=11521, title='Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=high,177%20genes%20which%20were%20involved')
20. AnnotationURLCitation(end_index=11828, start_index=11648, title='Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=treatment%20significantly%20alleviated%20HFD,nuclear%20Nrf2%20translocation%2C%20increased%20the')
21. AnnotationURLCitation(end_index=12125, start_index=11945, title='Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=treatment%20significantly%20alleviated%20HFD,nuclear%20Nrf2%20translocation%2C%20increased%20the')
22. AnnotationURLCitation(end_index=12518, start_index=12339, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid')
23. AnnotationURLCitation(end_index=12837, start_index=12658, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid')
24. AnnotationURLCitation(end_index=13341, start_index=13167, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=match%20at%20L427%20were%20remarkably,staining%2C%20lipid')
25. AnnotationURLCitation(end_index=13512, start_index=13342, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=2C%2CE%29,amounts%20of%20hepatic%20macrophages%20were')
26. AnnotationURLCitation(end_index=13818, start_index=13625, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=macrophage%20polarization%20and%20its%20relative,Mechanically%2C%20myricetin')
27. AnnotationURLCitation(end_index=14015, start_index=13819, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=therefore%20mitigated%20NASH%20and%20hepatic,induced%20NASH%20model%20in%20mice')
28. AnnotationURLCitation(end_index=14406, start_index=14241, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=match%20at%20L483%20treated%20NASH,9%29%2C%20and')
29. AnnotationURLCitation(end_index=14903, start_index=14721, title='Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=and%20increased%20antioxidative%20enzyme%20activities%2C,peroxisome%20and%20the%20PPAR%20signaling')
30. AnnotationURLCitation(end_index=15394, start_index=15212, title='Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=and%20increased%20antioxidative%20enzyme%20activities%2C,peroxisome%20and%20the%20PPAR%20signaling')
31. AnnotationURLCitation(end_index=15684, start_index=15500, title='Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=and%20increased%20antioxidative%20enzyme%20activities%2C,of%20PPAR%CE%B3%2C%20and%20normalized%20the')
32. AnnotationURLCitation(end_index=16071, start_index=15907, title='Molecular Medicine Reports', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=In%20the%20liver%2C%20alcohol%20is,3%20%29%20%28%2058%2C43')
33. AnnotationURLCitation(end_index=16206, start_index=16072, title='Molecular Medicine Reports', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=recent%20years,37%20%2C%2058')
34. AnnotationURLCitation(end_index=16508, start_index=16338, title='Molecular Medicine Reports', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=match%20at%20L661%2038%C2%A0%20,Article%20%3A%20Google%20Scholar')
35. AnnotationURLCitation(end_index=17089, start_index=16924, title='Molecular Medicine Reports', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=dietary%20structure%20of%20an%20individual%2C,37%20%2C%2058')
36. AnnotationURLCitation(end_index=18215, start_index=18107, title='Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/480183/#:~:text=prothrombin,increase%20in%20the')
37. AnnotationURLCitation(end_index=19007, start_index=18831, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=match%20at%20L407%20agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1')
38. AnnotationURLCitation(end_index=19164, start_index=19008, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1')
39. AnnotationURLCitation(end_index=19602, start_index=19446, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1')
40. AnnotationURLCitation(end_index=20357, start_index=20177, title='Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=treatment%20significantly%20alleviated%20HFD,nuclear%20Nrf2%20translocation%2C%20increased%20the')
41. AnnotationURLCitation(end_index=20537, start_index=20358, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid')
42. AnnotationURLCitation(end_index=21410, start_index=21231, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid')
43. AnnotationURLCitation(end_index=21576, start_index=21411, title='Molecular Medicine Reports', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=dietary%20structure%20of%20an%20individual%2C,37%20%2C%2058')
44. AnnotationURLCitation(end_index=23436, start_index=23254, title='Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=and%20increased%20antioxidative%20enzyme%20activities%2C,peroxisome%20and%20the%20PPAR%20signaling')
45. AnnotationURLCitation(end_index=24003, start_index=23825, title='Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=From%20initially%20screened%20395%20articles%2C,with%20a%20significantly%20greater%20decrease')
46. AnnotationURLCitation(end_index=24097, start_index=24004, title='Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=controls')
47. AnnotationURLCitation(end_index=24711, start_index=24618, title='Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=controls')
48. AnnotationURLCitation(end_index=25200, start_index=25019, title='Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39204178/#:~:text=multifaceted%20roles%20of%20cholesterol%20metabolism,future%20research%20and%20clinical%20applications')
49. AnnotationURLCitation(end_index=25377, start_index=25201, title='Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/39204178/#:~:text=recent%20advancements%20in%20understanding%20these,natural%20products%20in%20MASLD%2C%20providing')
50. AnnotationURLCitation(end_index=25669, start_index=25504, title='Molecular Medicine Reports', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=dietary%20structure%20of%20an%20individual%2C,37%20%2C%2058')
51. AnnotationURLCitation(end_index=26063, start_index=25879, title='Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=and%20increased%20antioxidative%20enzyme%20activities%2C,of%20PPAR%CE%B3%2C%20and%20normalized%20the')
52. AnnotationURLCitation(end_index=27672, start_index=27564, title='Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/480183/#:~:text=prothrombin,increase%20in%20the')
53. AnnotationURLCitation(end_index=27895, start_index=27719, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=match%20at%20L407%20agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1')
54. AnnotationURLCitation(end_index=28140, start_index=27961, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid')
55. AnnotationURLCitation(end_index=30172, start_index=29994, title='Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=From%20initially%20screened%20395%20articles%2C,with%20a%20significantly%20greater%20decrease')
56. AnnotationURLCitation(end_index=30266, start_index=30173, title='Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12274038/#:~:text=controls')
57. AnnotationURLCitation(end_index=30727, start_index=30629, title='KoreaMed Synapse', type='url_citation', url='https://synapse.koreamed.org/articles/1016286#:~:text=PPAR,C%29%20levels')
58. AnnotationURLCitation(end_index=30925, start_index=30788, title='KoreaMed Synapse', type='url_citation', url='https://synapse.koreamed.org/articles/1016286#:~:text=statins,considerable%20anticipation%20for%20the%20results')
59. AnnotationURLCitation(end_index=31236, start_index=31078, title='Reversal of orotic acid-induced fatty liver in rats by clofibrate - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/839735/#:~:text=Immunoelectrophoretic%20determinations%20show%20that%20the,fed%20control%20levels')
60. AnnotationURLCitation(end_index=31803, start_index=31627, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=match%20at%20L407%20agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1')
61. AnnotationURLCitation(end_index=31960, start_index=31804, title='Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion‐transporting polypeptides (OATP1B1 and OATP2B1) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11440035/#:~:text=agreement%20,binding%2Fassociation%20constants%20and%20assuming%201%3A1')
62. AnnotationURLCitation(end_index=32547, start_index=32368, title='Frontiers | Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis', type='url_citation', url='https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00071/full#:~:text=were%20remarkably%20attenuated%20in%20NASH,staining%2C%20lipid')
63. AnnotationURLCitation(end_index=33167, start_index=32997, title='Molecular Medicine Reports', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=match%20at%20L661%2038%C2%A0%20,Article%20%3A%20Google%20Scholar')
64. AnnotationURLCitation(end_index=33582, start_index=33417, title='Molecular Medicine Reports', type='url_citation', url='https://www.spandidos-publications.com/10.3892/mmr.2025.13452#:~:text=dietary%20structure%20of%20an%20individual%2C,37%20%2C%2058')
65. AnnotationURLCitation(end_index=34054, start_index=33946, title='Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/480183/#:~:text=prothrombin,increase%20in%20the')
66. AnnotationURLCitation(end_index=34565, start_index=34411, title='Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11045356/#:~:text=to%20address%20these%20issues%20but,the%20disease%20in%20the%20future')
67. AnnotationURLCitation(end_index=35065, start_index=34885, title='Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5188454/#:~:text=treatment%20significantly%20alleviated%20HFD,nuclear%20Nrf2%20translocation%2C%20increased%20the')